[1] Block TM,Gish R,Guo H,et al. Chronic hepatitis B:what should be the goal for new therapies Antiviral Res,2013,98(1):27-34.
[2] McMahon BJ,Holck P,Bulkow L,et al. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med,2001,135(9):759-768.
[3] Liaw YF,Sheen IS,Chen TJ,et al.Incidence,determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology,1991,13(4):627-631.
[4] Chu CM,Liaw YF.HBsAg seroclearance in asymptomatic carriers of high endemic areas:appreciably high rates during a long-term follow-up. Hepatology,2007,45(5):1187-1192.
[5] McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology,2009,49(Suppl 5):S45-55.
[6] Buti M,Tsai N,Petersen J,et al.Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci,2015,60(5):1457-1464.
[7] European Association For The Study Of The L. EASL clinical practice guidelines:Management of chronic hepatitis B virus infection. J Hepatol,2012,57(1):167-185.
[8] Chevaliez S,Hezode C,Bahrami S,et al.Long-term hepatitis B surface antigen(HBsAg) kinetics during nucleoside/nucleotide analogue therapy:finite treatment duration unlikely. J Hepatol,2013,58(4):676-683.
[9] Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med,2005,352(26):2682-2695.
[10] Marcellin P,Lau GK,Bonino F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeAg-negative chronic hepatitis B. New Engl J Med,2004,351(12):1206-1217.
[11] Marcellin P,Boyer N,Asselah T.Medical therapy of patients affected by HBeAg-negative chronic hepatitis B. Minerva Gastroenterol Dietol,2006,52(1):23-38.
[12] Marcellin P,Bonino F,Lau GK,et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology,2009,136(7):2169-2179,e1-4.
[13] Cao Z,Liu Y,Ma L,et al.A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology,2017,66(4):1058-1066.
[14] Buster EH,Hansen BE,Lau GK,et al.Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology,2009,137(6):2002-2009.
[15] Janssen HL,van Zonneveld M,Senturk H,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet,2005,365(9454):123-129.
[16] Lin B,Ha NB,Liu A,et al.Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol,2013,28(5):855-860.
[17] Zoutendijk R,Hansen BE,van Vuuren AJ, et al. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis,2011,204(3):415-418.
[18] Marcellin P,Ahn SH,Chuang WL,et al.Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Therapeut,2016,44(9):957-966.
[19] Marcellin P,Ahn SH,Ma X,Caruntu FA,et al.Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology,2016,150(1):134-144,e10.
[20] Hu P,Shang J,Zhang W,et al.HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog:New Switch Study. J Clin Transl Hepatol,2018,6(1):25-34.
[21] Ning Q,Han M,Sun Y,et al.Switching from entecavir to pegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:a randomised open-label trial (OSST trial). J Hepatol,2014,61(4):777-784.
[22] Gao Z,Zhu X,Lin B,et al.The optimizing treatment of peg interferon alfa in Hbeag negative chronic hepatitis B patients with low level HBsAg:A multicenter real world study (Interferon Cure Study,I CURE Study). Hepatology,2018,68(S1):246A.
[23] Blank A,Markert C,Hohmann N,et al.First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol,2016,65(3):483-489.
[24] Cai D,Mills C,Yu W,et al.Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother,2012,56(8):4277-4288.
[25] Ahmed M,Wang F,Levin A,et al.Targeting the achilles heel of the hepatitis B virus:a review of current treatments against covalently closed circular DNA. Drug Discov Today,2015,20(5):548-561.
[26] Schluep T,Lickliter J,Hamilton J,et al.Safety,tolerability,and pharmacokinetics of ARC-520 injection,an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection,in healthy volunteers. Clin Pharmacol Drug Dev,2017,6(4):350-362. |
